[ad_1]
The first highly effective human polyclonal antibody therapy specifically designed to treat rapidly mutating influenza A and B viruses
SAB Biotherapeutics (SAB) is a clinical-stage biopharmaceutical company with a new immunotherapy platform for the production of specific targeted, high-potency, fully human polyclonal antibodies, today announced that the first participant has been in its phase 2a clinical trial Administration to evaluate the safety and efficacy of SAB-176 in human challenge studies. SAB-176 is a new type of anti-influenza human immunoglobulin G (IgG) immunotherapy designed to address the limitations of current treatments for moderate to severe seasonal influenza. It is a high-potency multivalent human polyclonal antibody therapeutic agent, specifically designed to treat or prevent type A and type B seasonal and pandemic influenza virus infections.
“Due to the devastating effects of seasonal influenza on health and the economy, hundreds of thousands of people are hospitalized and die each year, more effective treatments are needed for moderate to severe cases. We are very happy to be able to advance SAB-176, which is A new type of high-efficiency immunotherapy, with SAB Biotherapeutics co-founder, president and chief executive officer Eddie J. Sullivan, said: “The unique ability to simultaneously target A and B influenza, including emerging and mutant strains. “SAB-176 has the potential to supplement the seasonal vaccine program, achieve better efficacy than small-molecule anti-influenza antiviral drugs in the general population, and serve as a valuable preventive agent in high-risk populations. We look forward to advancing this promising therapy, which utilizes the unique attributes of our fully human polyclonal antibody platform to deal with highly mutated viruses with significant annual health effects and pandemic potential. ”
The Phase 2a trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety and therapeutic effects of SAB-176 in 60 healthy adults challenged by the pandemic influenza virus strain (pH1N1).For more information about the study, please visit Clinical trial.gov (Identifier: NCT04850898). SAB-176 is also being evaluated in a phase 1 safety trial of increasing-dose, double-blind, randomized, placebo-controlled in healthy volunteers. SAB expects to report data from this study in the fourth quarter of 2021.
About SAB-176
SAB-176 is a multivalent, broadly neutralizing, fully human polyclonal antibody therapeutic candidate drug, which is being developed for the treatment or prevention of severe influenza. This novel, specifically targeted treatment method uses natural human biological immune responses to specifically bind to influenza A and B viruses. It can also be modified when needed to account for annual contingency changes. Preclinical data shows that SAB-176 can provide extensive protection against a variety of influenza…
The full story on Benzinga.com
[ad_2]
Source link
